| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epoprostenol | 23 | 2021 | 67 | 5.710 |
Why?
|
| Dinoprostone | 12 | 2023 | 76 | 5.110 |
Why?
|
| Intramolecular Oxidoreductases | 21 | 2021 | 56 | 4.500 |
Why?
|
| Cytochrome P-450 Enzyme System | 20 | 2021 | 135 | 3.840 |
Why?
|
| Cyclooxygenase 1 | 12 | 2021 | 40 | 3.500 |
Why?
|
| Arachidonic Acid | 12 | 2016 | 70 | 2.460 |
Why?
|
| Receptors, Thromboxane A2, Prostaglandin H2 | 10 | 2010 | 11 | 2.430 |
Why?
|
| Cyclooxygenase 2 | 10 | 2023 | 158 | 2.390 |
Why?
|
| Protein Engineering | 8 | 2021 | 74 | 1.980 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 6 | 2023 | 303 | 1.940 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2023 | 278 | 1.680 |
Why?
|
| Prostaglandin H2 | 8 | 2019 | 12 | 1.520 |
Why?
|
| Thromboxane A2 | 6 | 2023 | 19 | 1.430 |
Why?
|
| Prostaglandin-E Synthases | 6 | 2023 | 12 | 1.400 |
Why?
|
| Thromboxane-A Synthase | 7 | 2019 | 16 | 1.360 |
Why?
|
| Receptors, Prostaglandin | 6 | 2018 | 22 | 1.310 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2022 | 60 | 1.310 |
Why?
|
| Models, Molecular | 18 | 2008 | 1069 | 1.260 |
Why?
|
| Recombinant Fusion Proteins | 6 | 2019 | 768 | 1.180 |
Why?
|
| Magnetic Resonance Spectroscopy | 11 | 2017 | 286 | 1.120 |
Why?
|
| Antioxidants | 2 | 2021 | 332 | 1.100 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 7 | 2021 | 88 | 1.090 |
Why?
|
| Receptors, Epoprostenol | 8 | 2007 | 14 | 1.010 |
Why?
|
| Thromboxanes | 2 | 2023 | 10 | 0.970 |
Why?
|
| Alprostadil | 2 | 2017 | 28 | 0.930 |
Why?
|
| Drug Discovery | 3 | 2018 | 174 | 0.920 |
Why?
|
| Megakaryocytes | 1 | 2023 | 44 | 0.880 |
Why?
|
| Neurodegenerative Diseases | 2 | 2016 | 251 | 0.870 |
Why?
|
| Up-Regulation | 2 | 2020 | 870 | 0.860 |
Why?
|
| Thrombosis | 2 | 2021 | 505 | 0.840 |
Why?
|
| Ligands | 11 | 2018 | 537 | 0.810 |
Why?
|
| Cannabidiol | 1 | 2021 | 21 | 0.770 |
Why?
|
| Recombinant Proteins | 12 | 2021 | 1368 | 0.770 |
Why?
|
| Benzene Derivatives | 1 | 2021 | 19 | 0.760 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2021 | 102 | 0.740 |
Why?
|
| Protein Conformation | 13 | 2010 | 833 | 0.730 |
Why?
|
| Protein Binding | 14 | 2018 | 1734 | 0.720 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 8 | 2008 | 43 | 0.720 |
Why?
|
| HEK293 Cells | 6 | 2021 | 740 | 0.710 |
Why?
|
| Receptors, Prostaglandin E | 2 | 2011 | 10 | 0.690 |
Why?
|
| Binding Sites | 15 | 2017 | 1291 | 0.680 |
Why?
|
| Amino Acid Sequence | 19 | 2008 | 2677 | 0.680 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 199 | 0.660 |
Why?
|
| Receptors, Prostaglandin E, EP3 Subtype | 2 | 2017 | 4 | 0.650 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2011 | 18 | 0.640 |
Why?
|
| Molecular Sequence Data | 19 | 2008 | 3870 | 0.620 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 148 | 0.620 |
Why?
|
| Molecular Mimicry | 2 | 2008 | 24 | 0.610 |
Why?
|
| Disease Resistance | 1 | 2018 | 18 | 0.610 |
Why?
|
| Intracellular Membranes | 5 | 2006 | 64 | 0.590 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 3 | 2006 | 20 | 0.590 |
Why?
|
| Stroke | 2 | 2018 | 945 | 0.590 |
Why?
|
| Animals | 35 | 2021 | 33670 | 0.580 |
Why?
|
| Prostaglandins | 4 | 2018 | 48 | 0.570 |
Why?
|
| Endoplasmic Reticulum | 6 | 2016 | 213 | 0.570 |
Why?
|
| COS Cells | 9 | 2010 | 273 | 0.570 |
Why?
|
| Amino Acids | 1 | 2019 | 661 | 0.550 |
Why?
|
| Models, Chemical | 2 | 2007 | 86 | 0.550 |
Why?
|
| Protein Structure, Tertiary | 8 | 2005 | 751 | 0.550 |
Why?
|
| Microsomes | 5 | 2022 | 56 | 0.550 |
Why?
|
| Genetic Therapy | 5 | 2013 | 706 | 0.540 |
Why?
|
| Oxyquinoline | 1 | 2016 | 5 | 0.540 |
Why?
|
| Mutagenesis, Site-Directed | 7 | 2017 | 316 | 0.520 |
Why?
|
| Organometallic Compounds | 1 | 2016 | 106 | 0.520 |
Why?
|
| Cell Line | 10 | 2020 | 2787 | 0.520 |
Why?
|
| Endoplasmic Reticulum, Smooth | 1 | 2015 | 2 | 0.510 |
Why?
|
| Oxidative Stress | 2 | 2021 | 787 | 0.500 |
Why?
|
| Protein Structure, Secondary | 8 | 2015 | 238 | 0.500 |
Why?
|
| Peptide Fragments | 6 | 2015 | 748 | 0.500 |
Why?
|
| Humans | 52 | 2023 | 121743 | 0.470 |
Why?
|
| Hippocampus | 1 | 2020 | 805 | 0.460 |
Why?
|
| Insulin | 1 | 2019 | 1190 | 0.460 |
Why?
|
| Receptors, Thromboxane | 2 | 2003 | 5 | 0.440 |
Why?
|
| Cells, Cultured | 5 | 2011 | 3069 | 0.420 |
Why?
|
| Iloprost | 3 | 2020 | 10 | 0.410 |
Why?
|
| Stem Cell Transplantation | 2 | 2013 | 237 | 0.390 |
Why?
|
| Crystallography, X-Ray | 4 | 2017 | 353 | 0.380 |
Why?
|
| Peptides | 7 | 2015 | 799 | 0.380 |
Why?
|
| Signal Transduction | 5 | 2017 | 4504 | 0.380 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 840 | 0.370 |
Why?
|
| Hypertension, Pulmonary | 3 | 2013 | 422 | 0.370 |
Why?
|
| Myocardial Infarction | 2 | 2018 | 992 | 0.360 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2010 | 20 | 0.360 |
Why?
|
| Platelet Aggregation | 5 | 2019 | 120 | 0.350 |
Why?
|
| Heart Diseases | 2 | 2013 | 480 | 0.350 |
Why?
|
| Models, Biological | 1 | 2015 | 1434 | 0.350 |
Why?
|
| Mice, Transgenic | 4 | 2020 | 2438 | 0.350 |
Why?
|
| Adipocytes | 1 | 2011 | 158 | 0.340 |
Why?
|
| Neurons | 1 | 2020 | 1916 | 0.340 |
Why?
|
| Catalysis | 3 | 2021 | 125 | 0.330 |
Why?
|
| Antihypertensive Agents | 2 | 2010 | 390 | 0.330 |
Why?
|
| Mutagenesis | 2 | 2007 | 352 | 0.330 |
Why?
|
| Solutions | 5 | 2008 | 65 | 0.330 |
Why?
|
| Embryonic Stem Cells | 1 | 2010 | 171 | 0.320 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2009 | 286 | 0.320 |
Why?
|
| Heart Arrest | 1 | 2013 | 341 | 0.310 |
Why?
|
| Disease Models, Animal | 3 | 2018 | 4278 | 0.310 |
Why?
|
| Down-Regulation | 1 | 2011 | 700 | 0.310 |
Why?
|
| Vasodilator Agents | 1 | 2010 | 202 | 0.310 |
Why?
|
| DNA, Complementary | 4 | 2017 | 459 | 0.300 |
Why?
|
| Regeneration | 1 | 2010 | 200 | 0.300 |
Why?
|
| Neoplasms | 2 | 2021 | 2748 | 0.280 |
Why?
|
| 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid | 4 | 2010 | 39 | 0.280 |
Why?
|
| Kinetics | 6 | 2009 | 1317 | 0.280 |
Why?
|
| Endometrium | 2 | 2006 | 274 | 0.270 |
Why?
|
| Prunella | 1 | 2006 | 2 | 0.270 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 437 | 0.270 |
Why?
|
| Prostaglandin Endoperoxides, Synthetic | 1 | 2005 | 6 | 0.260 |
Why?
|
| Biomimetic Materials | 1 | 2005 | 11 | 0.260 |
Why?
|
| Substrate Specificity | 4 | 2007 | 284 | 0.250 |
Why?
|
| Calcium Signaling | 3 | 2017 | 241 | 0.250 |
Why?
|
| Blood Pressure | 2 | 2013 | 1311 | 0.250 |
Why?
|
| Heart | 1 | 2010 | 719 | 0.250 |
Why?
|
| Catalytic Domain | 3 | 2016 | 154 | 0.240 |
Why?
|
| MicroRNAs | 1 | 2011 | 835 | 0.230 |
Why?
|
| Mice | 10 | 2020 | 17494 | 0.230 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 107 | 0.220 |
Why?
|
| Spectrometry, Fluorescence | 3 | 2010 | 87 | 0.220 |
Why?
|
| Transfection | 5 | 2013 | 1076 | 0.220 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 176 | 0.210 |
Why?
|
| Receptors, Cholinergic | 3 | 1992 | 84 | 0.200 |
Why?
|
| Blood Platelets | 2 | 2023 | 319 | 0.200 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2021 | 44 | 0.200 |
Why?
|
| Circular Dichroism | 3 | 2009 | 82 | 0.190 |
Why?
|
| Maze Learning | 2 | 2020 | 127 | 0.190 |
Why?
|
| Epithelial Cells | 1 | 2006 | 898 | 0.190 |
Why?
|
| Cannabis | 1 | 2021 | 41 | 0.190 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 152 | 0.190 |
Why?
|
| Penis | 2 | 2013 | 96 | 0.180 |
Why?
|
| Muscle, Smooth, Vascular | 3 | 2013 | 238 | 0.180 |
Why?
|
| Celecoxib | 1 | 2019 | 31 | 0.170 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 2010 | 313 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 2 | 2011 | 330 | 0.170 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 337 | 0.170 |
Why?
|
| Hemostatics | 1 | 2019 | 53 | 0.160 |
Why?
|
| Models, Animal | 1 | 2021 | 465 | 0.160 |
Why?
|
| Sequence Alignment | 3 | 2005 | 615 | 0.160 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2005 | 654 | 0.160 |
Why?
|
| Spodoptera | 2 | 2008 | 44 | 0.160 |
Why?
|
| Baculoviridae | 2 | 2008 | 64 | 0.160 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 168 | 0.160 |
Why?
|
| Myocytes, Smooth Muscle | 2 | 2012 | 158 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2021 | 296 | 0.160 |
Why?
|
| NFATC Transcription Factors | 1 | 2018 | 41 | 0.160 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2018 | 38 | 0.160 |
Why?
|
| Tryptophan | 2 | 2009 | 92 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2018 | 79 | 0.150 |
Why?
|
| Drug Design | 3 | 2008 | 148 | 0.150 |
Why?
|
| Cell Survival | 1 | 2020 | 817 | 0.140 |
Why?
|
| Colon | 1 | 2019 | 347 | 0.140 |
Why?
|
| Peptides, Cyclic | 2 | 2003 | 53 | 0.140 |
Why?
|
| Cloning, Molecular | 2 | 2008 | 887 | 0.140 |
Why?
|
| Genetic Vectors | 3 | 2013 | 968 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2017 | 86 | 0.140 |
Why?
|
| Conserved Sequence | 2 | 2008 | 292 | 0.130 |
Why?
|
| Stem Cells | 2 | 2012 | 704 | 0.130 |
Why?
|
| Inflammation | 2 | 2016 | 1393 | 0.130 |
Why?
|
| Hemorrhage | 1 | 2019 | 457 | 0.130 |
Why?
|
| Protein Domains | 1 | 2017 | 228 | 0.130 |
Why?
|
| Molecular Weight | 1 | 2015 | 393 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2015 | 119 | 0.120 |
Why?
|
| In Vitro Techniques | 2 | 2008 | 971 | 0.120 |
Why?
|
| Ophiopogon | 1 | 2014 | 1 | 0.120 |
Why?
|
| Apoptosis | 4 | 2018 | 1788 | 0.120 |
Why?
|
| Prostaglandins I | 1 | 2013 | 2 | 0.110 |
Why?
|
| Protein Transport | 1 | 2015 | 369 | 0.110 |
Why?
|
| Computer Simulation | 2 | 2007 | 605 | 0.110 |
Why?
|
| Monocrotaline | 1 | 2013 | 3 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2019 | 558 | 0.110 |
Why?
|
| Disulfides | 2 | 2004 | 78 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2013 | 11 | 0.110 |
Why?
|
| Gene Expression | 2 | 2008 | 1579 | 0.110 |
Why?
|
| Cattle | 2 | 2005 | 555 | 0.110 |
Why?
|
| Hydrazines | 2 | 2003 | 28 | 0.110 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 476 | 0.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 2 | 2003 | 39 | 0.110 |
Why?
|
| Arginine | 2 | 2006 | 303 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2003 | 64 | 0.110 |
Why?
|
| Polysaccharides | 1 | 2014 | 141 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2014 | 139 | 0.110 |
Why?
|
| Mutation | 3 | 2017 | 5749 | 0.110 |
Why?
|
| Penile Erection | 1 | 2013 | 67 | 0.110 |
Why?
|
| Calcium | 2 | 2011 | 1095 | 0.100 |
Why?
|
| Cell Engineering | 1 | 2012 | 21 | 0.100 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 688 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1680 | 0.100 |
Why?
|
| Base Sequence | 4 | 2006 | 3114 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 711 | 0.100 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2011 | 43 | 0.100 |
Why?
|
| Erabutoxins | 1 | 1991 | 3 | 0.100 |
Why?
|
| Cobra Neurotoxin Proteins | 1 | 1991 | 6 | 0.100 |
Why?
|
| Mitochondria | 1 | 2016 | 666 | 0.100 |
Why?
|
| Behavior, Animal | 1 | 2013 | 476 | 0.090 |
Why?
|
| Point Mutation | 2 | 2011 | 346 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 1891 | 0.090 |
Why?
|
| Acetylcholine | 1 | 1991 | 82 | 0.090 |
Why?
|
| Bungarotoxins | 1 | 1990 | 15 | 0.090 |
Why?
|
| Feeder Cells | 1 | 2010 | 9 | 0.090 |
Why?
|
| Feces | 1 | 2014 | 692 | 0.090 |
Why?
|
| Growth Inhibitors | 1 | 2010 | 39 | 0.090 |
Why?
|
| Memory | 1 | 2013 | 355 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2010 | 1102 | 0.090 |
Why?
|
| Biocatalysis | 1 | 2009 | 33 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2013 | 520 | 0.080 |
Why?
|
| Biomarkers | 2 | 2019 | 2922 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 268 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2012 | 522 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1679 | 0.080 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2008 | 10 | 0.080 |
Why?
|
| Thromboxane B2 | 1 | 2008 | 20 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2010 | 180 | 0.080 |
Why?
|
| Radioligand Assay | 1 | 2008 | 26 | 0.080 |
Why?
|
| Phospholipids | 1 | 2009 | 107 | 0.080 |
Why?
|
| Structure-Activity Relationship | 3 | 2006 | 571 | 0.080 |
Why?
|
| Liposomes | 1 | 2009 | 167 | 0.080 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2009 | 425 | 0.080 |
Why?
|
| Titrimetry | 1 | 2007 | 7 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2011 | 492 | 0.080 |
Why?
|
| Crystallography | 1 | 2007 | 35 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2007 | 96 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 135 | 0.070 |
Why?
|
| Protons | 1 | 2007 | 92 | 0.070 |
Why?
|
| DNA Primers | 2 | 2006 | 667 | 0.070 |
Why?
|
| Anxiety | 1 | 2013 | 947 | 0.070 |
Why?
|
| Rats, Inbred F344 | 2 | 2019 | 104 | 0.070 |
Why?
|
| Plant Structures | 1 | 2006 | 3 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2008 | 353 | 0.070 |
Why?
|
| Peroxisome Proliferator-Activated Receptors | 1 | 2006 | 13 | 0.070 |
Why?
|
| Templates, Genetic | 1 | 2005 | 95 | 0.070 |
Why?
|
| Anti-Obesity Agents | 1 | 2006 | 32 | 0.060 |
Why?
|
| Phenylalanine | 1 | 2006 | 122 | 0.060 |
Why?
|
| Sequence Analysis, Protein | 1 | 2005 | 49 | 0.060 |
Why?
|
| Interleukin-1 | 1 | 2006 | 142 | 0.060 |
Why?
|
| Alanine | 1 | 2006 | 181 | 0.060 |
Why?
|
| Cell Proliferation | 2 | 2018 | 2309 | 0.060 |
Why?
|
| Enzyme Inhibitors | 2 | 2006 | 581 | 0.060 |
Why?
|
| Neoplasm Transplantation | 2 | 2018 | 376 | 0.060 |
Why?
|
| Sulfonamides | 1 | 2006 | 258 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2018 | 697 | 0.060 |
Why?
|
| Gastrointestinal Tract | 1 | 2006 | 207 | 0.060 |
Why?
|
| Biomarkers, Tumor | 1 | 2011 | 1424 | 0.060 |
Why?
|
| Antibody Specificity | 2 | 2002 | 208 | 0.050 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2003 | 22 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 442 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2004 | 138 | 0.050 |
Why?
|
| Rhodopsin | 1 | 2003 | 66 | 0.050 |
Why?
|
| DNA | 2 | 2003 | 1607 | 0.050 |
Why?
|
| Cell Membrane | 1 | 2005 | 463 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2019 | 11685 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 389 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2010 | 1923 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 138 | 0.050 |
Why?
|
| Coronary Vessels | 1 | 2006 | 528 | 0.050 |
Why?
|
| Fallopian Tubes | 1 | 2002 | 72 | 0.050 |
Why?
|
| Muscle Contraction | 1 | 2002 | 185 | 0.050 |
Why?
|
| Binding Sites, Antibody | 1 | 2002 | 99 | 0.050 |
Why?
|
| Rats | 3 | 2013 | 3653 | 0.050 |
Why?
|
| Male | 6 | 2020 | 59138 | 0.050 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2002 | 108 | 0.050 |
Why?
|
| Myasthenia Gravis | 2 | 1992 | 71 | 0.050 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2004 | 253 | 0.050 |
Why?
|
| Oxygen | 1 | 2002 | 544 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2018 | 98 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2010 | 1810 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2018 | 78 | 0.040 |
Why?
|
| Time Factors | 1 | 2008 | 5995 | 0.040 |
Why?
|
| Calcineurin | 1 | 2018 | 100 | 0.040 |
Why?
|
| Female | 6 | 2018 | 64492 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 660 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 1996 | 64 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1996 | 221 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 765 | 0.030 |
Why?
|
| Epitopes | 2 | 1992 | 426 | 0.030 |
Why?
|
| Succinic Acid | 1 | 2014 | 14 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 1992 | 286 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 77 | 0.030 |
Why?
|
| Prebiotics | 1 | 2014 | 21 | 0.030 |
Why?
|
| Fermentation | 1 | 2014 | 62 | 0.030 |
Why?
|
| Purines | 1 | 2014 | 107 | 0.030 |
Why?
|
| Familial Primary Pulmonary Hypertension | 1 | 2013 | 19 | 0.030 |
Why?
|
| Nerve Crush | 1 | 2013 | 11 | 0.030 |
Why?
|
| Autoantibodies | 2 | 1992 | 421 | 0.030 |
Why?
|
| Plant Extracts | 1 | 2014 | 117 | 0.030 |
Why?
|
| 4-Aminopyridine | 1 | 2012 | 32 | 0.030 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 122 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 63 | 0.030 |
Why?
|
| Culture Media, Conditioned | 1 | 2012 | 79 | 0.030 |
Why?
|
| Half-Life | 1 | 2012 | 159 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 2013 | 318 | 0.030 |
Why?
|
| Fear | 1 | 2013 | 198 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 221 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 539 | 0.020 |
Why?
|
| Tissue Engineering | 1 | 2013 | 169 | 0.020 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2011 | 71 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 156 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 3288 | 0.020 |
Why?
|
| Torpedo | 1 | 1991 | 37 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 1992 | 154 | 0.020 |
Why?
|
| Neovascularization, Physiologic | 1 | 2012 | 205 | 0.020 |
Why?
|
| Actins | 1 | 2013 | 340 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 257 | 0.020 |
Why?
|
| Computer Graphics | 1 | 1990 | 38 | 0.020 |
Why?
|
| Metabolomics | 1 | 2014 | 389 | 0.020 |
Why?
|
| Hypoxia | 1 | 2012 | 246 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2013 | 1209 | 0.020 |
Why?
|
| Adenoviridae | 1 | 2013 | 638 | 0.020 |
Why?
|
| Intestines | 1 | 2014 | 571 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2011 | 808 | 0.020 |
Why?
|
| Microbiota | 1 | 2014 | 390 | 0.020 |
Why?
|
| Survival Rate | 1 | 2013 | 1983 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 4333 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 334 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2009 | 726 | 0.020 |
Why?
|
| Software | 1 | 1990 | 671 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2012 | 1524 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2006 | 240 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2004 | 285 | 0.010 |
Why?
|
| Prostaglandins H | 1 | 2002 | 4 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2006 | 157 | 0.010 |
Why?
|
| Tritium | 1 | 2002 | 177 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 2002 | 75 | 0.010 |
Why?
|
| Phenotype | 1 | 2012 | 4207 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 249 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1295 | 0.010 |
Why?
|
| Atherosclerosis | 1 | 2006 | 818 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2009 | 2868 | 0.010 |
Why?
|
| Valine | 1 | 1996 | 106 | 0.010 |
Why?
|
| Rabbits | 1 | 1996 | 722 | 0.010 |
Why?
|
| T-Lymphocytes | 2 | 1992 | 1673 | 0.010 |
Why?
|
| Pyridostigmine Bromide | 1 | 1992 | 13 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 111 | 0.010 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 1992 | 5 | 0.010 |
Why?
|
| Leukemia, Erythroblastic, Acute | 1 | 1992 | 13 | 0.010 |
Why?
|
| Prednisone | 1 | 1992 | 272 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1992 | 260 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1992 | 271 | 0.010 |
Why?
|
| Polyethylene Glycols | 1 | 1992 | 216 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 422 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 1992 | 689 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 1992 | 1591 | 0.000 |
Why?
|
| RNA, Messenger | 1 | 1992 | 2826 | 0.000 |
Why?
|
| Aged | 1 | 1992 | 18464 | 0.000 |
Why?
|
| Adolescent | 1 | 1992 | 18879 | 0.000 |
Why?
|
| Middle Aged | 1 | 1992 | 25388 | 0.000 |
Why?
|
| Adult | 1 | 1992 | 28623 | 0.000 |
Why?
|